Does SHPH pay a dividend and is it safe?

Shuttle Pharmaceuticals Holdings Inc. (SHPH) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / SHPH / dividends

CRVO (28) CELU (26) MIRA (36) BYSI (37) ⌘ Pro Terminal →

Shuttle Pharmaceuticals Holdings Inc. (SHPH) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.95 -3.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.91

Shuttle Pharmaceuticals Holdings Inc. (SHPH) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $24.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SHPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SHPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.95 (-3.88% 1D, market cap $24.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SHPH compare to CRVO and CELU in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SHPH carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRVO (CervoMed Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $24.2M) and CELU (Celularity Inc. (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $26.0M). Among the 5-stock peer group, SHPH leads on earnings multiple (N/A) while SHPH leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SHPH?

▼

Per SHPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001757499), Shuttle Pharmaceuticals Holdings Inc. generated $33.4M in revenue (+54.8% YoY), -$11.7M in net income, and -$9.5M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.91 (-0.89%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SHPH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY SHPH SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 57.4 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.18-5.2% Next Q

Q2 (-2Q)

Grade D$4.91+6.1% Next Q

Q3 (-1Q)

Grade D$5.21-5% Next Q

Current

Grade D-$4.95-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SHPH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SHPH currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.24) and Max Pain ($5.20) forces dealer call-delta covering toward $46.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SHPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SHPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SHPH)

✓Walkthrough of SHPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SHPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.15%▲ ASCENDING CHANNEL

2026-11-03O $5.23H $5.23L $4.95C $4.95VOL 20.5K

RES: $6.19SUP: $3.38SMA50: $4.24SMA200: $6.95

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SHPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SHPH Butterfly Map → + Track SHPH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +54.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SHPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SHPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SHPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SHPH)

Health Care Rank #449 of 1015 ⚔️ CRVO vs SHPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SHPH vs. CRVO, CELU, MIRA, BYSI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Shuttle Pharmaceuticals Holdings Inc. (SHPH) ranks #449 by composite RQD confidence (41/100, grade D-) and #817 by equity capitalization ($24.5M). Within this direct 5-issuer industry benchmark cohort, SHPH leads on earnings valuation at N/A trailing P/E, while SHPH leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SHPH currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SHPH ACTIVE Shuttle Pharmaceuticals Holdings Inc.	D-	41/100	—	—	-35.0%	-3.88%	$24.5M	Benchmark Subject
CRVO CervoMed Inc.	E	28/100	—	—	-35.0%	+2.50%	$24.2M	/crvo-vs-shph →
CELU Celularity Inc. (Class A)	E	26/100	—	24.4%	-35.0%	+0.30%	$26.0M	/celu-vs-shph →
MIRA MIRA Pharmaceuticals Inc.	D-	36/100	—	—	-35.0%	-2.06%	$23.0M	/mira-vs-shph →
BYSI BeyondSpring Inc.	D-	37/100	—	—	-35.0%	+25.18%	$26.5M	/bysi-vs-shph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001757499 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shuttle Pharmaceuticals Holdings Inc. (SHPH) reported GAAP revenue of $33.4M (+54.8% vs. FY2024 revenue of $21.5M , and +102.2% cumulative change since FY2023) , GAAP net income of -$11.7M, operating cash flow of -$9.5M, and free cash flow of -$9.5M (-29.4% YoY). On the balance sheet, SHPH closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.4M	-$11.7M	-$9.5M	-$9.5M	$10.5M	—
FY2024 (FY)	2024-12-31	$21.5M	-$9.1M	-$7.3M	-$7.3M	$2.5M	—
FY2023 (FY)	2023-12-31	$16.5M	-$6.6M	-$5.6M	-$5.6M	—	—

3. SHPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SHPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SHPH compare to CRVO and CELU in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SHPH?

Where is SHPH trading relative to its 50-day, 200-day, and 52-week technical levels?

SHPH last traded at $4.95 (-3.88% on volume of 92,223 shares), positioning the stock +16.75% above its 50-day simple moving average ($4.24) and -28.78% below its 200-day simple moving average ($6.95). Across its 52-week range of $2.58 to $44.40, SHPH sits at the 5.7% percentile with a 14-day RSI of 57.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.33 to $5.57).

Direct Sub-Reports: SHPH RQD Cockpit SHPH 12M Forecast SHPH Earnings & Move SHPH Dividends & DRIP SHPH Insiders & 13F SHPH Whale Options SHPH Profit Sankey SHPH News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SHPH — Shuttle Pharmaceuticals Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Shuttle Pharmaceuticals Holdings Inc. (SHPH) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.95 (-3.88% 1D, market capitalization $24.5M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Shuttle Pharmaceuticals Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its products, customers, or revenue model. Reported revenue is — for each of FY 2025, FY 2024, and FY 2023. —: product pipeline, end customers, and monetization mechanism.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Shuttle Pharmaceuticals Holdings Inc. (SHPH) reported $33.4M in annual revenue (up from $21.5M in FY2024, +54.8% YoY) and -$11.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($16.5M revenue, -$6.6M net income) through FY2025, SHPH scaled operating cash flow to -$9.5M and free cash flow to -$9.5M, backed by $10.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.58 – $44.40 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Per the Butterfly graph, supply_chain is NONE and butterfly_links is empty, so no upstream or downstream dependencies are mapped. —: supplier, customer, and partner relationships. The only sector context is Health Care / Biotechnology: Pharmaceutical Preparations. Investors should watch the auditor transition as a 2nd-order governance bottleneck, since an unfilled audit role could delay reporting. The liquidity beta is a macro sensitivity rather than an operating linkage, and its weak correlation limits its predictive use.

Key Question #1: Can SHPH sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $33.4M and free cash flow of -$9.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SHPH's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SHPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Shuttle Pharmaceuticals Holdings Inc. (SHPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SHPH Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 1d ago

Shuttle Pharmaceuticals Holdings, Inc. Estimates – NASDAQ:SHPH

TradingView report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

Let's take a look at the stocks that are in motion in today's session.

ChartMill report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An auditor exit awaits Q3 reporting at Shuttle Pharma (SHPH), with no successor engaged as of Oct. 16.

Stock Titan report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Citius Oncology, Inc. (CTOR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Shuttle Pharmaceuticals (SHPH) Slips 1.83% to $5.35, Nearing Key Support - Up Down Ratio

https://www.dars.gov.et/ report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Largest Companies by Market Cap: U.S. Stocks

TradingKey report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ChartMill • 1d ago

Traders are paying attention to the gapping stocks in Thursday's session.

ChartMill report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 2d ago

Top Republic Power Group Limited Class A Ordinary Shares (RPGL) Competitors 2026

MarketBeat report covering Shuttle Pharmaceuticals Holdings Inc. (SHPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SHPH Bull vs. Bear Conversation Board — What's Your Call at $4.95?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SHPH 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $6.28 (+21.9%)

📌 Pinned Debate

The Butterfly graph flags a BULLISH liquidity tailwind with a Macro Tailwind Score of 90/100, though its correlation is weak (r = -0.16

Picked up a starter position in SHPH in my $100K Virtual Cash book at $5.15. The Butterfly graph flags a BULLISH liquidity tailwind with a Macro Tailwind Score of 90/100, though its correlation is weak (r = -0.16).. Trading inside a $2.58–$44.40 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

Both sides have a point here — SHPH's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $4.22 (-18.1%)

Spot @ $5.15

With zero reported revenue, ROIC of -35%, FCF of -$9.5M in FY 2025, and an auditor exit pending, the balance sheet and cash flow are we

Here is the bear case nobody on the bull side wants to address on SHPH: With zero reported revenue, ROIC of -35%, FCF of -$9.5M in FY 2025, and an auditor exit pending, the balance sheet and cash flow are weak.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.